Positive lymph node ratio is an index in predicting prognosis for remnant gastric cancer with insufficient retrieved lymph node in R0 resection

Honghu Wang1,2, Hao Qi1,2, Xiaofang Liu1, Ziming Gao1, Iko Hidasa1, Ailixier Aikebaier1 & Kai Li1*

The staging system of remnant gastric cancer (RGC) has not yet been established, with the current staging being based on the guidelines for primary gastric cancer. Often, surgeries for RGC fail to achieve the > 15 lymph nodes needed for TNM staging. Compared with the pN staging system, lymph node ratio (NR) may be more accurate for RGC staging and prognosis prediction. We retrospectively analyzed the data of 208 patients who underwent R0 gastrectomy with curative intent and who have ≤ 15 retrieved lymph nodes (RLNs) for RGC between 2000 and 2014. The patients were divided into four groups on the basis of the NR cutoffs: rN0: 0; rN1: > 0 and ≤ 1/6; rN2: > 1/6 and ≤ 1/2; and rN3: > 1/2. The 5-year overall survival (OS) rates for rN0, rN1, rN2, and rN3 were 84.3%, 64.7%, 31.5%, and 12.7%, respectively. Multivariable analyses revealed that tumor size (p = 0.005), lymphovascular invasion (p = 0.023), and NR (p < 0.001), but not pN stage (p = 0.682), were independent factors for OS. When the RLN count is ≤ 15, the NR is superior to pN as an important and independent prognostic index of RGC, thus predicting the prognosis of RGC patients more accurately.

Remnant gastric cancer (RGC) is an unusual but important type of gastric cancer (GC) comprising malignant tumors in the remnant stomach after subtotal distal gastrectomy, regardless of whether the initial disease is benign or malignant as well as the duration between the initial operation and diagnosis1. RGC is rare, accounting for only approximately 1–8% of all GC cases2, but its incidence has been rising owing to the increase in early GC incidence, which, in turn, is due to improvements in medical examination and the prolonged survival of patients with primary GC3,4. Despite its difference from other GC types, RGC staging is still based on the TNM staging system of GC. However, a retrieved lymph node (RLN) count of ≤ 15 may lead to false staging and affect treatment plans and prognosis. Furthermore, most RGC patients are in the advanced stage because of the lack of specific symptoms during the early stage, which leads to a lower radical resection rate and poor prognosis5. The metastatic lymph node (LN) ratio (NR) is reported to be more suitable for primary GC staging compared to a positive LN count, especially when the RLN is low6. This study aimed to develop a more accurate staging system for RGC. We hypothesize that NR would be more exact than the UICC/AJCC pN stage (8th edition) for RGC staging, which we validated through a retrospective analysis.

Methods

Patients. Written informed consent was obtained from all the patients. The study was approved by the Research Ethics Committee of the Affiliated Hospital of China Medical University and all experiments were performed in accordance with relevant guidelines and regulations. We established a retrospectively maintained database of all patients with RGC who underwent surgery at the Department of Oncology, First Affiliated Hospital of China Medical University between January 2000 and December 2014. Of them, we evaluated 243 patients who underwent radical (R0) surgery (with D2 lymphadenectomy) for RGC. However, only 7 of these patients had lymph node metastases > 15, and considering that this number of cases is too small to be representative, we finally excluded them. Surgery had been performed in all patients using an open approach, with the second sur-
gery being total gastrectomy with Roux-en-Y anastomosis. None of the patients received neoadjuvant chemotherapy. All of the study participants were followed up through telephone or written communications until death or end of the study period (December 31, 2015). We declared that the informed consent from patients has been obtained prior to our study. As some patients involved in our study died during the follow up, we obtained the informed consent from their guardians.

The median and mean follow-up periods were 60 and 83.15 months (range 1–346 months), respectively. In total, 11 patients were lost to follow-up, and 17 died during the postoperative period. Finally, 208 patients were included in the analysis. Postoperative chemotherapy regimens included 5-fluorouracil (5-FU) plus cisplatin, 5-FU plus mitomycin and epirubicin, 5-FU plus leucovorin and cisplatin, 5-FU plus cisplatin and epirubicin, and cisplatin plus oxaliplatin.

Data collection. Data of the following variables were collected: (1) gender (male or female); (2) age (≤ 60 or > 60 years); (3) tumor size (≤ 4 cm or > 4 cm); (4) macroscopic serosal classification (normal, reactive, nodular, tendonoid, and color-diffused type); (5) Borrmann type (Borrmann 1, 2, 3, and 4); (6) depth of tumor invasion according to the 8th UICC/AJCC (T1, T2, T3, T4a, or T4b); (7) Lauren’s classification (intestinal or diffuse); (8) histology (differentiated or undifferentiated); (9) lymphovascular invasion; (10) number of positive LNs according to the 8th UICC/AJCC (N0, N1, N2, or N3); (11) NR (0, 0–1/6, 1/6–1/2, > 1/2); and (12) postoperative adjuvant therapy.

Retrieved lymph node categories. The best cut-off approach was used to determine LN ratio categories, with patient survival (log-rank statistic) as the dependent variable. Accordingly, 1/6 and 1/2 were identified as the best cutoff for discriminating differential prognoses in RGC patients. Thus, patients were divided into four groups: rN0, NR = 0; rN1, > 0 and ≤ 1/6; rN2, > 1/6 and ≤ 1/2; and rN3, > 1/2. Cases in which the retrieved LN was 0 were considered as N0 and NR = 0.

Statistical analyses. All statistical analyses were performed using SPSS software version 20.0. We used the Kaplan–Meier method to determine overall survival (OS) and the log-rank test for comparison. Cox’s proportional hazard model (forward-stepwise method) was used for the multivariate analysis to determine the independent factors for prognosis prediction. We divided the multivariate analysis into two steps. In step 1, we analyzed all significantly important prognostic factors using multivariate analysis, with the exception of the revised NR stage. In step 2, we performed multivariate analysis with consideration of all significantly important prognostic factors, including the revised NR stage. Two-tailed p-values and differences were considered significant at p < 0.05.

Results Clinicopathological characteristics and prognostic factors. The clinicopathological characteristics of the 208 patients are summarized in Table 1. The NR distribution was as follows: rN0, 108 patients (36.6%); rN1, 51 patients (17.3%); rN2, 73 patients (24.7%); rN3, 63 patients (21.4%). Univariate analysis showed that tumor size (≤ 4 cm vs. > 4 cm, p < 0.001), Borrmann type (high vs. low, p < 0.001), histology (differentiated vs. undifferentiated, p = 0.011), Lauren classification (intestinal vs. diffuse, p = 0.001), lymphovascular invasion (positive vs. negative, p < 0.001), pT stage (early vs. advanced, p < 0.001), pN stage (early vs. advanced, p < 0.001), NR (high vs. low, p < 0.001), and postoperative adjuvant therapy (yes vs. no, p = 0.031), but not gender, age, and macroscopic serosal classification, (p = 0.113, 0.393, and 0.084, respectively), were significantly correlated with OS after curative surgery (Table 2). The mean survival of each pN stage was 131.34 ± 6.49, 73.14 ± 7.25, 36.37 ± 3.72, and 25.7 ± 5.78 months, whereas the mean survival for each NR stage was 131.34 ± 6.49, 91.35 ± 9.48, 46.96 ± 5.65, and 33.33 ± 2.36 months, respectively.

Multivariate analyses. To determine which is more accurate between pN stage and NR stage as a prognostic index for the OS of RGC patients, we conducted a two-step multivariate analysis of prognosis. In step 1, we performed a multivariate analysis of all the important prognostic factors (tumor size, Borrmann type, histology, Lauren classification, lymphovascular invasion, pT stage, pN stage, postoperative adjuvant therapy), except for NR staging. We found that tumor size (p = 0.007), lymphovascular invasion (p = 0.002), and pN stage (p < 0.001) were independent factors predicting prognosis (Table 2). However, NR stage was superior to pN stage (UICC/AJCC) as an independent prognostic indicator (Table 2), as determined in step 2 of the analysis. Moreover, pT stage was remarkably not an independent prognostic index for RGC patients, according to our analysis.

Migration. We further calculated the migration among the different stages according to the new NR stages. We found that 25 and 5 cases of pN1 were re-divided into rN2 and rN3, and 33 cases of pN2 were re-divided into rN3, respectively (Table 3A). Migration of the corresponding modified TNM stage using NR (mTNM-NR) staging was also observed, as shown in Table 3B.

As shown in Fig. 1, there was a significant difference in prognosis between pN and NR stages among the RGC patients. According to the analysis, there was no significant difference between pN2 and pN3 (p = 0.511), but there was a significant difference between rN2 and rN3 (p = 0.034) in their predictive capability for the prognosis of RGC patients. In addition, we presented the Kaplan–Meier curves based on the TNM staging (UICC/AJCC 8th edition) and mTNM-NR staging system as shown in Fig. 2.
### Table 1. Descriptive data of the patients involved in this cohort (n = 208). UICC union for international cancer control, AJCC American joint committee on cancer, NR lymph node ratio.

| Patient characteristics          | n  | %   |
|----------------------------------|----|-----|
| **Age (years)**                  |    |     |
| ≤ 60                             | 109| 52.4|
| > 60                             | 99 | 47.6|
| **Gender**                       |    |     |
| Male                             | 166| 79.8|
| Female                           | 42 | 20.2|
| **Tumor size (cm)**              |    |     |
| ≤ 4 cm                           | 83 | 39.9|
| > 4 cm                           | 125| 60.1|
| **Borrmann type**                |    |     |
| Borrmann 1                        | 9  | 4.3 |
| Borrmann 2                        | 53 | 25.5|
| Borrmann 3                        | 128| 61.5|
| Borrmann 4                        | 18 | 8.7 |
| **Macroscopic serosal classification** |     |     |
| Normal                           | 12 | 5.8 |
| Reactive                         | 31 | 14.9|
| Nodular                          | 71 | 34.1|
| Tendonoid                        | 70 | 33.7|
| Color-diffused                   | 24 | 11.5|
| **Histology**                    |    |     |
| Undifferentiated                 | 116| 55.8|
| Differentiated                   | 92 | 44.2|
| **Lauren’s classification**      |    |     |
| Intestinal                       | 112| 53.8|
| Diffuse                          | 96 | 46.2|
| **Lymphovascular invasion**      |    |     |
| Positive                         | 43 | 20.7|
| Negative                         | 165| 79.3|
| **8th UICC/AJCC pT stage**       |    |     |
| T1                               | 8  | 3.9 |
| T2                               | 35 | 16.8|
| T3                               | 103| 49.5|
| T4a                              | 33 | 15.9|
| T4b                              | 29 | 13.9|
| **8th UICC/AJCC pN stage**       |    |     |
| N0                               | 76 | 36.5|
| N1                               | 66 | 31.7|
| N2                               | 59 | 28.4|
| N3a/3b                           | 7  | 3.4 |
| **NR**                           |    |     |
| 0                                | 76 | 36.5|
| > 0, ≤ 1/6                       | 36 | 17.3|
| > 1/6, ≤ 1/2                     | 52 | 25  |
| > 1/2                            | 44 | 21.2|
| **Postoperative adjuvant therapy**|     |     |
| Yes                              | 33 | 15.9|
| No                               | 175| 84.1|

**Correlations analysis.** We further analyzed the correlation between NR and other clinicopathologic features. As shown in Table 4, there was significant positive correlation between NR and the following parameters: tumor size (p = 0.000), Borrmann type (p = 0.000), macroscopic serosal classification (p = 0.002), Lauren’s
Table 2. Univariate analysis and two-step multivariate analysis for overall survival. 5-YSR 5-year survival rate, UICC union for international cancer control, AJCC American joint committee on cancer, HR hazard ratio, CI confidence interval, NR lymph node ratio. a Step 1, with consideration of all significantly important prognostic factors in the univariate analysis, with the exception of the revised NR stage. b Step 2, with consideration of all significantly important prognostic factors in the univariate analysis, including the revised NR stage.

|                                | Univariate analysis | Multivariate analysis step 1<sup>a</sup> | Multivariate analysis step 2<sup>b</sup> |
|--------------------------------|---------------------|------------------------------------------|------------------------------------------|
|                                | n | 5-YSR% | ×2 | p  | HR    | 95% CI  | p  | HR    | 95% CI  | p  |
| Age (years)                    |   |        |    |    |       |         |    |       |         |    |
| ≤ 60                           | 109 | 54.8   | 0.731 | 0.393 |       |         |    |       |         |    |
| > 60                           | 99 | 50.0   |       |       |       |         |    |       |         |    |
| Gender                         |   |        |    |    |       |         |    |       |         |    |
| Male                           | 166 | 50.2   | 2.510 | 0.113 |       |         |    |       |         |    |
| Female                         | 42 | 61.7   |       |       |       |         |    |       |         |    |
| Tumor size (cm)                |   |        |    |    |       |         |    |       |         |    |
| ≤ 4 cm                         | 83 | 66.9   | 19.486 | 0.000 | 0.007 | 1.151–2.471 | 0.005 | 1.171–2.493 |
| > 4 cm                         | 125 | 42.9   |       |       | 1.687 | 1.151–2.471 | 1.708 | 1.171–2.493 |
| Borrmann type                  |   |        |    |    |       |         |    |       |         |    |
| Borrmann 1                     | 9 | 84.6   | 19.795 | 0.000 |       |         |    |       |         |    |
| Borrmann 2                     | 53 | 67.6   |       |       |       |         |    |       |         |    |
| Borrmann 3                     | 128 | 47.8   |       |       |       |         |    |       |         |    |
| Borrmann 4                     | 18 | 26.9   |       |       |       |         |    |       |         |    |
| Macropscopic serosal classification | 8.226 | 0.084 |       |       |       |         |    |       |         |    |
| Normal                         | 12 | 64.7   |       |       |       |         |    |       |         |    |
| Reactive                       | 31 | 59.1   |       |       |       |         |    |       |         |    |
| Nodular                        | 71 | 56.4   |       |       |       |         |    |       |         |    |
| Tendonoid                      | 70 | 48.5   |       |       |       |         |    |       |         |    |
| Color-diffused                 | 24 | 38.2   |       |       |       |         |    |       |         |    |
| Histology                      |   |        |    |    |       |         |    |       |         |    |
| Undifferentiated               | 116 | 46.1 | 6.422 | 0.011 |       |         |    |       |         |    |
| Differentiated                 | 92 | 60.8   |       |       |       |         |    |       |         |    |
| Lauren's classification        |   |        |    |    | 10.096 | 0.001 |       |         |    |
| Intestinal                     | 112 | 61.6 |       |       |       |         |    |       |         |    |
| Diffuse                        | 96 | 41.9   |       |       |       |         |    |       |         |    |
| Lymphovascular invasion        |   |        |    |    |       |         |    |       |         |    |
| Positive                       | 43 | 36.1   | 12.524 | 0.000 | 0.002 | 0.645–0.941 | 0.023 | 0.442–0.941 |
| Negative                       | 165 | 56.8 | 0.542 | 0.370–0.792 |       |         |    |       |         |    |
| 8th UICC/AJCC pT stage         |   |        |    |    | 40.325 | 0.000 |       |         |    |
| T1                             | 8 | 100.0 |       |       |       |         |    |       |         |    |
| T2                             | 35 | 69.4 |       |       |       |         |    |       |         |    |
| T3                             | 103 | 55.5 |       |       |       |         |    |       |         |    |
| T4a                            | 33 | 36.2 |       |       |       |         |    |       |         |    |
| T4b                            | 29 | 26.8 |       |       |       |         |    |       |         |    |
| 8th UICC/AJCC pN stage         |   |        |    |    | 103.539 | 0.000 |       |         |    |
| N0                             | 76 | 84.3 |       |       |       |         |    |       |         |    |
| N1                             | 66 | 48.4 | 3.668 | 2.094–4.625 |       |         |    |       |         |    |
| N2                             | 59 | 21.4 | 8.186 | 4.748–14.114 |       |         |    |       |         |    |
| N3a/3b                         | 7 | 10.0 | 9.960 | 4.367–22.716 |       |         |    |       |         |    |
| NR                             |   |        |    |    | 125.406 | 0.000 |       |         |    |
| 0                              | 76 | 84.3 |       |       |       |         |    |       |         |    |
| >0, ≤ 1/6                      | 36 | 64.7 | 2.396 | 1.234–4.654 |       |         |    |       |         |    |
| >1/6, ≤ 1/2                    | 52 | 31.5 | 6.102 | 3.484–10.689 |       |         |    |       |         |    |
| > 1/2                          | 44 | 12.7 | 9.867 | 5.641–17.259 |       |         |    |       |         |    |
| Postoperative adjuvant therapy |   |        |    |    | 4.629 | 0.031 |       |         |    |
| Yes                            | 33 | 66.0 |       |       |       |         |    |       |         |    |
| No                             | 175 | 50.0 |       |       |       |         |    |       |         |    |
classification (0.009), and pT stage (0.000). And a negative correlation was shown between NR and histology (p = 0.007), lymphovascular invasion (0.003).

**Characteristic of lymph nodes metastasis.** The total number of lymph nodes retrieved was 1152, of which 426 were metastases. We present the distribution and basic statistics of the total retrieved LN numbers with metastatic LN numbers in Table 5.

**Discussion**

While RGC has been extensively studied, its staging system is yet to be established. Therefore, RGC staging generally follows the TNM staging of primary GC\(^1\). In the 8th UICC/AJCC TNM staging system, the amount of metastatic LNs is used to determine the LN stage, and the number of RLNs must be > 15 to arrive at a more accurate LN staging. However, this appears to be inappropriate for RGC where RLNs can be < 16, particularly in the case of radical lymphadenectomy for initial malignant disease\(^8\). Previous studies have shown that LN metastasis is an independent risk factor in RGC local recurrence. Moreover, complete resection and LN dissection are key to successful radical gastrectomy for RGC. Thus, appropriate LN staging can accurately indicate patient prognosis, guiding further treatment. By contrast, inadequate LN dissection can lead to residual cancer cells, which results in a higher recurrence rate after surgery. Ultimately, it remains unclear whether the 8th UICC/AJCC pN staging can accurately assess the prognosis of RGC patients.

|   | pN (8th UICC/AJCC) | NR |
|---|-------------------|----|
| pN1 vs rN1 | 66 | 36 |
| pN2 vs rN2 | 59 | 51 |
| pN3 vs rN3 | 7  | 45 |

**Table 3.** Migration between numeric-based versus lymph node ratio-based staging systems for remnant gastric cancer. (A) pN (8th UICC/AJCC) vs. NR staging systems, (B) TNM (8th UICC/AJCC) vs. mTNM-NR staging systems. UICC union for international cancer control, AJCC American joint committee on cancer, NR lymph node ratio.

Figure 1. Comparison of survival curves according to the pN and NR stages (both p < 0.001). (a) Survival curves of patients with various pN stages. (b) Survival curves of patients with various NR stages. NR lymph node metastatic ratio.
Figure 2. Kaplan–Meier curves. (a) Kaplan–Meier curves according to the TNM (8th UICC/AJCC) classification system. (b) Kaplan–Meier curves according to the mTNM-NR classification system. UICC union of international cancer control, AJCC American joint committee on cancer, NR lymph node metastatic ratio, mTNM-NR modified TNM stage using NR.

Table 4. Correlation between NR and other clinicopathologic parameters. *Correlation is significant at the 0.01 level (2-tailed).

| NR                          | Pearson correlation | P (two-tailed) |
|-----------------------------|--------------------|----------------|
| Age                         | 0.084              | 0.151          |
| Gender                      | 0.018              | 0.759          |
| Tumor size                  | 0.222              | 0.000          |
| Borrmann type               | 0.249              | 0.000          |
| Macroscopic serosal classification | 0.179       | 0.002          |
| Histology                   | −0.158             | 0.007          |
| Lauren's classification     | 0.151              | 0.009          |
| Lymphovascular invasion     | −0.173             | 0.003          |
| 8th UICC/AJCC pT stage      | 0.322              | 0.000          |
| Postoperative adjuvant therapy | −0.083           | 0.155          |

Table 5. Characteristic of lymph nodes metastasis.
NR is the ratio of the amount of positive LN to that of the RLN. Despite the same number of metastases, cases with higher RLN and thus lower NR have better prognosis⁹. Due to the common occurrence of low RLN cases during RGC resection, we hypothesized that NR was more accurate than the present pN stage, which was confirmed by our results. The NR classification system stratifies the pN stage better; in our analysis, we used a multiple Cox regression model to select the NR stage as a substitute for the pN stage. In addition, lymphovascular invasion and tumor size were also proven to be independent risk indexes for prognosis.

The NR system has obvious advantages and attractive prospects for clinical application in RGC. Dapeng et al. showed that NR plays a role as an independent prognostic factor after radical operation for GC⁹⁰. Lee et al. also suggested that among patients with stage IIIA GC, the prognosis differed between those with RLN ≤ 15 and > 15⁹¹. Ichikura's study found that the amount of positive LNs is closely related to the RLN¹². Both a low and exceedingly high RLN may lead to inaccurate staging, leading to inaccurate assessments of patient prognosis. Therefore, some researchers suggested using the LN metastasis rate for LN staging as it can reflect both the amount of dissected LN and positive LN¹³. On the other hand, there is no consensus on the prognostic value of NR in RGC patients.

Lu et al. reported that the tumor size may be more hierarchical than the pN (7th UICC) stage system in RGC¹⁴. Similarly, we found that tumor size is an independent risk factor of prognosis. RGC is complicated to manage because of its diversity, and the initial operation significantly influences the second operation. Most researchers stipulate that initial gastrectomy alters the lymph flow from the remnant stomach and LN metastasis due to reconstruction and adhesion, leading to the occurrence of RGC¹⁵,¹⁶. Several authors have reported that the risk of RGC was higher after Billroth II reconstruction. Gandolfi et al. found that Billroth II was the most commonly used approach (95%) for reconstruction during the initial surgery of RGC patients¹⁷. With respect to the type of surgical anastomosis, it was reported that compared with Billroth I, Billroth II surgery increased the risk of RGC by four times¹⁸. Xiang et al. found that RGC mostly occurred at the anastomotic sites, and that LN metastasis of the jejunal mesentery was universal, particularly in patients who underwent Billroth II anastomoses¹⁹. In addition, our results demonstrate that T stage was not an independent prognostic factor for patients with RGC. We speculated that RCG is characterized by alterations in the normal anatomic lymphatic flow of the stomach and its association with the surrounding tissue. Adhesion after primary operation may influence the progression of cancer and the infiltration of surrounding organs, especially for RGC at the anastomosis site. In our study, we enrolled 208 RGC cases, there were mainly cases with the depth of invasion at T2 (n = 35, 16.8%), T3 (n = 103, 49.5%) and T4 (n = 62, 29.8%). Only 8 cases were T1 stage (3.9%). Alberto et al.¹⁹ reported that RGC with pT1 stage had lower rate of lymph node metastasis. Once the depth of invasion was T2 or above, the rate of LN metastasis increased significantly. The lymph node dissection for RGC should be extended beyond the initial operation. A high incidence of LN metastasis in the No. 10–14, 20, 110, 111 was found in the patients who had previously undergone gastric reconstruction. All the regional lymph nodes around the stomach that were not cleared in initial operation should be dissected. The LN metastasis rate was 42.9%, 34.2%, 15.9%, 29.2% and 37.2% in No. 10, 11, 12, 14 and 20 in our study. Therefore, it is not at all surprised that N categories replaced T categories being an independent risk factor for prognosis of RGC. In addition, the small sample size may contribute this result. We also observed LN metastasis of the jejunal mesentery during RGC surgeries (n = 2). However, this needs to be further validated and analyzed in future research.

In contrast to our findings, some studies reported that only pT and pN are the prognostic factors of RGC. Nakagawa et al. performed a similar study but obtained a contrasting conclusion, stating that NR was not better to pN (7th UICC)⁴. The contrasting findings may be attributed to the different NR cut-off points and the eligibility criteria between the current study and that by Nakagawa et al. In Nakagawa’s study, the NR cut-offs were 0; > 0, ≤ 0.1; > 0.1, ≤ 0.4; and < 0.4. When Marchet analyzed the clinical data of 1853 patients with gastric cancer, NR was divided into 0%, 1–9%, 10–25%, and > 25%²⁰. Satio et al. divided NR stages into 0%, > 5%, 5–10%, 10–20%, 20–30%, and > 30%, and found that NR was an independent prognostic factor in patients with gastric cancer; however, the number of positive LNs was not an independent factor²¹. Bando et al.²² studied 650 GC patients who had > 15 LN dissections after operation. Their NR staging was divided into 0%, < 10%, 10–25%, and > 25%, and they found that NR staging was more effective than the JGCA LN staging. Moreover, Sun et al. identified the following best-fit cut-off values: rN0: 0%; rN1: 1–20%; rN2: 21–50% and rN3: > 50%, proving the advantage of NR stage in minimizing stage migration for GC patients with insufficient number or level of retrieved LNs²³. Furthermore, few scholars have elaborated on the method of dividing NR staging nodes. There is no international consensus; hence, further research is needed to determine the appropriate staging nodes. In our study, we identified the NR stages as rN0: 0; rN1: > 0 and ≤ 1/6; rN2: > 1/6 and ≤ 1/2; and rN3: > 1/2.

Moreover, a significant portion of patients included in our study underwent Billroth I and Roux-Y during the initial surgical reconstruction (n = 41, 21%). However, we only focused on those who underwent Billroth II. In addition, we included cases with RLN ≤ 15, and excluded the very few cases with RLN > 16. By contrast, Nakagawa et al. included both cases of RLN ≤ 15 and > 15. One study showed that if the number of RLN after radical gastrectomy was > 15, then the prognostic value of NR for patients with GC was worse than that of N stage⁴, supporting our findings that NR stage can predict the prognosis of RGC patients more accurately than pN stage.

Our study has some limitations. First, it spanned a relatively long period of 15 years. Continuous improvements in surgical instrumentation and chemotherapy regimens may have affected the outcomes. We also evaluated a specific sample population, and thus, our findings need to be further validated in other types of RGC patients and cohorts, particularly in the Western population. Because the number of cases with RLN > 15 is too small to be representative, our study included only samples with ≤ 15 RLN. This may limit the possibility of the NR staging system being developed as a standard staging system in clinical practice, and our findings should hence be verified by further big data studies. We suggest that for RGC with RLN > 15, the original pN stage (8th edition) can be used.
In conclusion, the metastatic LN ratio is an independent prognostic index for patients with RGC. When the amount of RLN is ≤ 15, the NR stage can more accurately predict the prognosis of patients with RGC than the pN stage, facilitating the selection of better treatment options.

Data availability
At present, the datasets generated during and analyzed during the current study are being used in another research; hence, these are not publicly available but could be available from the corresponding author on reasonable request.

Received: 17 May 2020; Accepted: 18 December 2020
Published online: 21 January 2021

References
1. Nienhüser, H. et al. Gastric stump carcinoma: Frequency, treatment, complications and prognosis. Chirurg 88(4), 317–327 (2017).
2. Pasechnikov, V., Chukov, S., Fedorov, E., Kikuste, I. & Leja, M. Gastric cancer: Prevention, screening and early diagnosis. World. J. Gastroenterol. 20(38), 13842–13862 (2014).
3. Zhang, Y. et al. Staging for remnant gastric cancer: The metastatic lymph node ratio vs. the UICC 7th Edition System. Ann. Surg. Oncol. 23(13), 4322–4331 (2016).
4. Okines, A. et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21, v50–v54 (2010).
5. Gholami, S. et al. Number of lymph nodes removed and survival after gastric cancer resection: An analysis from the US gastric cancer collaborative. J. Am. Coll. Surg. 221(2), 291–299 (2015).
6. Huang, C. et al. Lymph node ratio is a critical prognostic predictor in gastric cancer treated with S1 chemotherapy. Gastric Cancer 17(1), 67–75 (2014).
7. Lin, D. et al. Lymph node ratio is an independent prognostic factor in gastric cancer after curative resection (R0) regardless of the examined number of lymph nodes. Am. J. Clin. Oncol. 36(4), 325–330 (2013).
8. Lee, H. et al. Influence of the number of lymph nodes examined on staging of gastric cancer. Br. J. Surg. 88(10), 1408–1412 (2011).
9. Fujii, T. et al. Minimum number of lymph nodes that should be examined for the International Union Against Cancer/American Joint Committee on Cancer TNM classification of gastric carcinoma. World. J. Surg. 27(3), 330–333 (2003).
10. Lu, J. et al. Prognostic value of tumor size in patients with remnant gastric cancer: Is the seventh UICC stage sufficient for predicting prognosis? PLoS ONE 9(12), e115776 (2014).
11. Tanigawa, N. et al. Current state of gastric stump carcinoma in Japan: Based on the results of a nationwide survey. World. J. Surg. 34(7), 1540–1547 (2010).
12. Xiang, H., Da-yu, T. & Liang, C. Clinicopathological features of patients with gastric stump carcinoma after a distal gastrectomy. Chin. J. Practical. Surg. 29(16), 828–832 (2009).
13. Gandolfi, L. et al. Cancer of gastric stump in Italy, 1979–1986. Gastrointest. Endosc. 34(3), 242–246 (1988).
14. Lundegårdh, G. et al. Stomach cancer after partial gastrectomy for benign ulcer disease. N. Engl. J. Med. 319(4), 195–200 (1988).
15. Alberto, D. L. et al. Gastric stump cancer after distal gastrectomy for benign disease: Clinicopathological features and surgical outcomes. Ann. Surg. Oncol. 21(8), 2594–2600 (2014).
16. Alberto, M. et al. The ratio between metastatic and examined lymph nodes(N ratio) is an independent prognostic factor in gastric cancer regardless of the type of lymphadenectomy: Results from an Italian multicentric study in 1853 patients. Ann. Surg. 245(4), 543–552 (2007).
17. Hiroaki, S. Prognostic significance of the ratio between metastatic and dissected lymph nodes (n ratio)in patients with advanced gastric cancer. J. Surg. Oncol. 97(2), 132–135 (2008).
18. Btsuro, B. et al. Outcome of ratio of lymph node metastasis in gastric carcinoma. Ann. Surg. Oncol. 9(6), 775–784 (2002).
19. Sun, Z. et al. The impact of N-ratio in minimizing stage migration phenomenon in gastric cancer patients with insufficient number or level of lymph node retrieved: Results from a Chinese mono-institutional study in 2159 patients. Ann. Oncol. 20, 897–905 (2009).
20. Deng, J. Y. et al. The most appropriate category of metastatic lymph nodes to evaluate overall survival of gastric cancer following curative resection. J. Surg. Oncol. 98(5), 343–348 (2008).

Acknowledgements
This research was supported by Department of Surgical Oncology, First Affiliated Hospital of China Medical University, which provided the data used in our analyses. This study was supported by the Key Research and Development Program for Scientific Innovation of Shenyang City(19-112-4-104) and Millions of Leading Engineering Talents Program(XLYC1905004). The funders had no role in study design, data collection and analysis, preparation or publish of the manuscript.

Author contributions
W.H.H. and Q.H. have contributed equally to this article and are joint first authors. W.H.H., Q.H., and L.K. wrote the main manuscript text. W.H.H., Q.H., H.L., and A.A. contributed to new reagents or analytic tools, and G.Z.M. and L.X.F. prepared the figures. W.H.H., Q.H., A.A. and L.K. revised the manuscript. All authors reviewed the manuscript.

Competing interests
The authors declare no competing interests.
